Aptorum Group Ltd Class A (APM) Stock Analysis

Aptorum Group Ltd Class A (APM) is a publicly traded company in the HEALTHCARE sector. It trades at $0.98, carries a market capitalization of $8.71M. This page summarizes the public market data, fundamentals, and frequently asked questions for APM, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About Aptorum Group Ltd Class A

Aptorum Group Ltd Class A is a London-based biotechnology firm dedicated to the discovery, development, and commercialization of innovative therapeutic solutions, with a primary focus on combating infectious diseases and various forms of cancer. The company boasts a robust pipeline of drug candidates, underpinned by cutting-edge research and proprietary technologies, which demonstrates its commitment to addressing significant unmet medical needs. With a strategic emphasis on rapidly advancing...

GNG Research Analysis

GNG Research scores Aptorum Group Ltd Class A (APM) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for APM.

Frequently Asked Questions

Does APM pay dividends?

Aptorum Group Ltd Class A (APM) does not currently pay a regular dividend.

What is APM's market cap?

Aptorum Group Ltd Class A (APM) has a market capitalization of $8.71M with a current stock price of $0.98.